Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy

Table 2 Growth curves in glioma cells exposed to vehicle or ketone bodies

21% O₂	3OHB	AcAc	LiCl	3OHB + AcAc	3OHB + LiCl
U87MG	94.9 ± 9.9	109.7 ± 10.3	104.5 ± 11.7	107.3 ± 10.1	100.8 ± 10.0
U251MG	100.2 ± 5.8	97.4 ± 5.5	97.0 ± 6.9	96.1 ± 5.4	90.2 ± 5.0
LNT-229	98.4 ± 4.7	100.6 ± 3.7	109.5 ± 7.9	104.0 ± 3.6	95.7 ± 4.0
T98G	96.3 ± 4.8	87.6 ± 4.0	91.2 ± 7.8	86.1 ± 5.3	88.0 ± 4.1
A172	97.1 ± 6.0	100.3 ± 5.7	99.9 ± 7.4	84.9 ± 10.7	90.7 ± 5.6
LNT-229 scrambled sh	99.9 ± 9.5	109.2 ± 6.0	103.7 ± 5.3	102.2 ± 6.2	97.5 ± 6.8
LNT-229 p53sh	98.3 ± 5.3	102.3 ± 3.2	96.5 ± 2.4	95.1 ± 2.4	95.0 ± 2.8
0.1% O ₂	3OHB	AcAc	LiCl	3OHB + AcAc	3OHB + LiCl
U87MG	97.7 ± 4.9	115.8 ± 5.8	115.2 ± 4.9	108.8 ± 4.2	104.0 ± 5.7
U251MG	96.6 ± 2.7	102.6 ± 5.0	98.1 ± 2.5	92.1 ± 5.4	86.9 ± 3.0
LNT-229	93.6 ± 3.5	103.2 ± 4.9	104.4 ± 3.3	97.0 ± 3.3	91.0 ± 5.1
T98G	98.8 ± 10.1	100.2 ± 9.1	97.3 ± 8.7	101.7 ± 7.3	91.5 ± 9.9
A172	107.9 ± 15.6	93.2 ± 9.2	95.8 ± 7.4	101.0 ± 8.7	91.6 ± 6.8
LNT-229 scrambled sh	99.6 ± 5.4	104.5 ± 4.7	105.4 ± 6.0	98.9 ± 4.6	103.9 ± 8.2
LNT-229 p53sh	94.8 ± 2.5	107.4 ± 4.2	107.6 ± 5.4	102.9 ± 4.0	96.0 ± 4.5

Cells were exposed to 3-hydroxybutyrate (3OHB, 5 mM), acetoacetate (AcAc, 5 mM), lithium chloride (LiCl, 5 mM) or both for 36 h at 21% or 0.1% O₂ and subsequently stained with crystal violet. Data are expressed as percentages (mean and standard deviation) relative to untreated control cells.

ISSN: 1471-2407